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Broad-range rDNA polymerase chain reaction (PCR) provides an alternative, cultivation-independent
approach for identifying pathogens. In 1995, the Centers for Disease Control and Prevention initiated pop-
ulation-based surveillance for unexplained life-threatening infections (Unexplained Death and Critical Ill-
ness Project [UNEX]). To address the causes of UNEX cases, we examined 59 specimens from 46 cases
by using broad-range bacterial 16S rDNA PCR and phylogenetic analysis of amplified sequences. Speci-
mens from eight cases yielded sequences from Neisseria meningitidis (cerebrospinal fluid from two
patients with meningitis), Streptococcus pneumoniae (cerebrospinal fluid from one patient with meningitis
and pleural fluid from two patients with pneumonia), or Stenotrophomonas maltophilia (bone marrow aspi-
rate from one patient with pneumonia). Streptococcus pneumoniae rDNA sequence microheterogeneity
was found in one pleural fluid specimen, suggesting the presence of multiple strains. In conclusion, known
bacterial pathogens cause some critical illnesses and deaths that fail to be explained with traditional diag-
nostic methods.
n 1995, the Centers for Disease Control and Prevention
(CDC) initiated a large-scale, population-based surveil-
lance study to detect life-threatening infectious diseases in pre-
viously healthy persons 1 to 49 years of age; this study is
known as the Unexplained Death and Critical Illness Project
(UNEX) (1). Surveillance was performed through the CDC
Emerging Infections Program sites in California (Alameda,
Contra Costa, and San Francisco counties), Connecticut (New
Haven County), Minnesota, and Oregon. At the start of the
project, the surveillance population base was 7.7 million. The
study design was a prospective case series obtained by
enhanced passive surveillance. Only cases from which cultures
and routine serologic tests failed to provide a microbiologic
diagnosis were selected for further study. Work-up of cases
was syndrome based and algorithm directed. Case investiga-
tion included laboratory analysis by broad-range 16S rDNA
polymerase chain reaction (PCR) to identify the presence of
bacteria in specimens collected from normally sterile anatomic
sites. 
Broad-range bacterial PCR is based on the use of primers
that recognize conserved sequences of bacterial chromosomal
genes encoding ribosomal RNA (rDNA). The resulting ampli-
fied rDNA sequences also contain variable regions and pro-
vide a reliable basis for the analysis of phylogenetic
relationships among different forms of cellular life. Broad-
range bacterial PCR has been used to identify previously
uncharacterized as well as known bacterial pathogens directly
in clinical specimens, including cerebrospinal fluid (CSF),
synovial fluid, blood, and heart valve tissue (2-9). The use of
broad-range bacterial 16S rDNA PCR for identifying bacterial
culture isolates in the clinical laboratory is well established
(10), and this technique is useful as a routine supplemental
method for direct bacterial detection from clinical specimens
(11). However, broad-range bacterial rDNA PCR has not pre-
viously been applied in a systematic manner for the diagnosis
of unexplained deaths and life-threatening illnesses with fea-
tures suggesting infection. In our study, we examined this
issue.
Materials and Methods
Patients and Specimens
Patients were recruited as part of the CDC Emerging Infec-
tions Program’s UNEX study and met all project inclusion cri-
teria, including absence of important preexisting medical
conditions, development of an illness with defined features
suggestive of infectious etiology, severity leading to admission
to an intensive care unit or to death, and failure of cultivation
and routinely available serologic tests to provide a microbio-
logic diagnosis (1). Of specimens available from more than
139 cases fulfilling these criteria, only those from anatomic
sites that are usually culture negative in healthy persons and
those from patients with syndromes of suspected bacterial eti-
ology were selected for broad-range bacterial PCR analysis.
These 59 specimens from 46 patients were collected from July
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1995 to January 2000. The median age of the 46 patients (21
female, 25 male) was 18.5 years (range 1 to 47 years). Most
had neurologic (n=17) or respiratory manifestations (n=14).
Five had cardiac, one had abdominal, and nine had multiorgan
manifestations. The patients resided in New Haven County
(CT) (n=5), Minnesota (n=6), Oregon (n=20), or three coun-
ties in the San Francisco Bay Area (n=15). 
Bacterial Strains
Partial 16S rDNA sequences were determined from three
Streptococcus pneumoniae clinical isolates obtained from
patients in the San Francisco Bay Area during 1997 and 1998
(strains SF10014, SF10175, and SF10314; California Depart-
ment of Health Services, Berkeley, CA). Escherichia coli
strain B DNA (Sigma, St. Louis, MO) was used as a positive
control and as template for measurement of PCR assay sensi-
tivity in reactions with primers fD1mod and 16S1RR-B (see
below). 
 Specimen Processing
Specimens were processed in parallel with interspersed
negative control specimens. DNA was extracted from serum
(n=4), blood (n=25), blood culture (n=9), and bone marrow
(n=2) specimens by using the chaotropic properties of guani-
dine isothiocyanate, followed by DNA extraction and purifica-
tion by alcohol precipitation with the IsoQuick Nucleic Acid
Extraction Kit (ORCA Research, Bothell, WA). Pleural fluid
(n=3) was digested with proteinase K (Sigma) and non-ionic
detergent, essentially as described (12). CSF (n=16) was pro-
cessed by either of these methods.
Broad-Range Bacterial rDNA PCR
All specimens were analyzed with PCR methods using at
least one of the following four bacterial broad-range 16S
rDNA primer pairs: fD1mod (5'-AGAGTTTGATCYTG-
GYTYAG-3', corresponding to positions 8-27 in the E. coli
16S rRNA gene) (4) and 16S1RR-B (5'-CTTTACGCCCAR-
TRAWTCCG-3', 575-556) (6); 63F (5'-CAGGCCTAACA-
CATGCAAGTC-3') (13) and 16S1RR-B; 8F2 (5'-
TGGAGAGTTTGATCCTGGCTCAG-3', 5-27) and 806R (5'-
GGACTACCAGGGTATCTAAT-3', 806-787) (3); and 515F
(5'-GTGCCAGCAGCCGCGGTAA-3', 515-533) (3) and 13R
(5'-AGGCCCGGGAACGTATTCAC-3', 1390-1371) (3). The
presence of amplifiable DNA and PCR inhibitors was assessed
with human beta-globin gene PCRs and primers PCO4 and
GH20 (3).
Forty-three specimens from 34 patients were analyzed
with primer pair fD1mod/16S1RR-B. Reactions based on
these primers contained 10 mM Tris-HCl pH 8.3, 50 mM KCl,
1.5 mM MgCl2, 200 µM each deoxynucleoside triphosphates,
2.5 U AmpliTaq LD DNA polymerase (PE Biosystems, Foster
City, CA), and 5-µL template, as well as 20 pmol of each
primer in a total volume of 50 µL. After a denaturation step of
3 min at 94°C, PCR steps at 94°C for 30 sec, 56°C for 30 sec,
and 72°C for 30 sec were repeated 30 to 36 times, followed by
an elongation step at 72°C for 7 min in a GeneAmp PCR sys-
tem 2400 thermal cycler (PE Biosystems). Products were
detected by agarose gel electrophoresis and DNA staining with
ethidium bromide. In most cases, the presence of product was
also assessed by attempting to generate recombinant plasmid
clones (see below). PCR amplification conditions used with
some other bacterial broad-range primer pairs included 100-
µL reaction volumes and a 4-min initial denaturation step.
Reactions with all reagents necessary for PCR, including
water processed in parallel with clinical specimens, were per-
formed as negative controls. 
DNA Sequence Determination and Phylogenetic Analysis
PCR products were sequenced directly, as well as after
cloning, by using the TA or TOPO cloning systems (Invitro-
gen, Carlsbad, CA). Automated ABI PRISM 373 or 377 DNA
sequencers (PE Biosystems) and BigDye Terminator Cycle
sequencing chemistry were used for determining DNA
sequences. Both DNA strands were analyzed, and base-editing
was performed together with manual review of the electro-
pherograms, using AutoAssembler (PE Biosystems). The 16S
rDNA sequences were compared with those in the GenBank
database by using the BLAST search tool (14). In addition, the
automated 16S rRNA sequence alignment tool and phyloge-
netic algorithms from the ARB software package (Technical
University of Munich, Germany) were used (15). Complete
sequences of the four rRNA operons of an S. pneumoniae sero-
type 4 strain were obtained from The Institute for Genomic
Research, Rockville, MD (16). Unpublished sequence data
from the rRNA operons of a different S. pneumoniae strain
were obtained from SmithKline Beecham, Philadelphia, PA.
Results
Bacterial 16S rDNA sequences were detected in specimens
from 8 of the 46 patients. When the same PCR conditions were
used, negative control reactions failed to yield a visible prod-
uct of the expected size. The absence of large amounts of
inhibitors of the PCR reaction in specimens from the remain-
ing 38 patients was demonstrated by the ability to amplify
human beta-globin sequences from those specimens. The spec-
imen types with positive bacterial 16S rDNA PCR results were
CSF (three patients), pleural fluid (two patients), bone marrow
aspirate (one patient), and blood culture bottle material (two
patients) (Table 1). The sensitivity of this PCR assay with
primers fD1mod/16S1RR-B was 5-50 E. coli 16S rDNA gene
copies, as assessed by using purified E. coli DNA as template.
CSF was studied from 14 project cases with unexplained
meningitis. Specimens from five subjects were analyzed with
broad-range bacterial rDNA primer pairs 8F2/806R and 515F/
13R. PCR products of approximately the anticipated size (804
and 876 bp, respectively) were generated from specimens from
cases XOR34 and XOR06. From case XOR34, a 1342-bp 16S
rRNA gene consensus sequence was generated from the over-
lapping gene fragments. This sequence shared 99.3% similar-
ity (1332/1342 nucleotide positions) with the four identicalRESEARCH
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16S rRNA gene sequences from each of the recently published
complete N. meningitidis serogroup A and B genomes (Gen-
Bank accession numbers AL162758 and AE002551); these
GenBank sequences were the closest match to the XOR34 case
sequence. Direct sequencing of PCR products from case
XOR06 generated 654 bp of sequence homologous to the N.
meningitidis serogroup A and B 16S rRNA genes. Limited
CSF from this case prevented a more complete sequence anal-
ysis of the bacterial rDNA in this specimen.
CSF from nine other patients was analyzed by using prim-
ers fD1mod/16S1RR-B. Two CSF specimens drawn on differ-
ent days from case XCA73 each generated PCR products
whose directly determined sequences were identical (526/526
bp) to the published 16S rDNA sequence from a S. pneumo-
niae reference strain (NCTC 7465T, AJ001246) and with the
16S rDNA sequences from three S. pneumoniae strains iso-
lated from patients in the same region and from the same time
period (SF10014, SF10175 and SF10314); these reference
sequences were determined as part of this study (Figure). The
sequences of two clones from each of the amplified XCA73
products were identical to the sequences obtained directly
from the PCR products. The CSF specimens from cases
XOR06, XOR34, and XCA73 had been collected after empiric
antibiotic therapy had begun.
From two of the three culture-negative pleural fluid speci-
mens (cases XEB44 and XMN22) DNA products of the
expected size (~568 bp) were amplified with bacterial broad
range primers fD1mod/16S1RR-B. In addition to analysis of
cloned molecules from these products, the PCR product from
case XEB44 was sequenced directly; insufficient product was
obtained from the pleural fluid of case XMN22 for direct
sequencing. From the XEB44 pleural fluid specimen, DNA
was also amplified with bacterial broad-range primers 63F/
16S1RR-B. Three recombinant plasmid clones from this prod-
uct were characterized by DNA sequencing (Table 2). One
clone sequence from each of the pleural fluid specimens
(clones C and G in Table 2) was identical (497/497 and 509/
509 bp) to an S. pneumoniae rDNA sequence deposited in
Table 1. Characteristics of the bacterial 16S rDNA broad-range polymerase chain reaction (PCR)-positive cases
Case ID Sex
Age
(yrs)
Duration of
antibiotic therapy 
before specimen 
obtained
Clinical
syndrome(s)a
16S rDNA
PCR and sequencing
results Specimen Outcome
XOR6 M 18 10 min Neurologic Neisseria meningitidis CSF Survived
XOR34 M 13 3 days Neurologic N. meningitidis CSF Survived
XCA73 F 19 1 dayb Respiratory &
 neurologic
Streptococcus 
 pneumoniae
CSF Survived
XEB44 F 10 3 days Respiratory  S. pneumoniae Pleural fluid Survived
XMN22 M 43 2 weeks Respiratory  S. pneumoniae Pleural fluid Survived
XOR63 M 29 1 month Respiratory  Stenotrophomonas
 maltophilia
Bone marrow 
aspirate
Died 
(no autopsy)
XOR56 M 11 none Multisystem Staphylococcus
epidermidis
Blood culture 
material
Survived
XCT29 F 10 1 week Cardiac Bacillus sp., Halomonas
 sp., Enterococcus sp.
Blood culture 
material
Survived
aThe primary clinical syndrome(s) during hospitalization.
bA second cerebrospinal (CSF) sample obtained 5 days later also contained S. pneumoniae rDNA.
Figure. Phylogenetic analysis of the bacterial 16S rDNA sequences
obtained from cases XEB44 and XMN22. The tree was rooted with Sta-
phylococcus aureus and Escherichia coli as outgroups and constructed
with a maximum-likelihood algorithm using 468 homologous sequence
positions that were selected from a sequence dataset of 497 total posi-
tions. Streptococcus pneumoniae clinical isolates sequenced for this
study are marked as SF10175, SF10314, and SF10014. GenBank
database accession numbers for published sequences are given in
parentheses. All six sequences from the case XCA73 cerebrospinal
fluid were identical to those of the S. pneumoniae reference strain
(accession no. AJ001246). PCR = polymerase chain reaction.Emerging Infectious Diseases  •  Vol. 8, No. 2, February 2002 191
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GenBank (reference strain NCTC 7465T, #AJ001246)(Figure).
However, four other clones from XEB44 (clones A, B, D, and
E) and one from XMN22 (clone F) contained one or two posi-
tions with variant nucleotides. This variability was confirmed
in case XEB44 by examining the sequence obtained directly
from the PCR product (Table 2, original PCR product). In con-
trast, ambiguities were not seen in directly sequenced PCR prod-
ucts from the three clinical isolates (SF10014, SF10175,
SF10314), nor in the sequences obtained from case XCA73 CSF. 
To understand better the variation observed in these pneu-
mococcal sequences, a model of the secondary structure of the
S. pneumoniae 16S rRNA was constructed, based on the pub-
lished secondary structure of the Bacillus subtilis homolog
(17) (supplemental data available at http://relman.stan-
ford.edu). Two of the five polymorphic positions are predicted
to participate in a “stem” structure and can therefore be
assessed for compensatory changes at the paired position. Of
the two, only the polymorphism at position 442 creates a non-
canonical pairing, thereby suggesting a possible Taq poly-
merase incorporation error. Intrachromosomal allelic
variability was another possible explanation for the observed
polymorphisms in these pleural fluid S. pneumoniae 16S
rDNA sequences. However, the complete genome sequence of
each of two S. pneumoniae strains contains four identical cop-
ies of the 16S rRNA operon (16) (unpub. data, Michael A.
Loretto and Martin Rosenberg). Therefore, our data are consis-
tent with the hypothesis that patient XEB44 was infected in the
pleural space by at least two different S. pneumoniae strains.
Insufficient amounts of data from the patient XMN22 speci-
men hamper speculation of a similar nature for this case. 
PCR analysis of a bone marrow aspirate from a case of
fatal respiratory disease (XOR63) showed a 16S rDNA
sequence that was 99.8% (527/528 bp) similar to 16S rDNA
sequences from Stenotrophomonas maltophilia (strain ATCC
13637, #AB008509). This sequence was obtained directly
from the PCR product as well as from two recombinant clones;
all were identical. A bone marrow aspirate from another
patient in our study did not reveal bacterial 16S rDNA
sequences.
Two blood culture bottle specimens (from cases XOR56
and XCT29) of nine that were studied gave positive results for
bacterial rDNA using PCR primer pair fD1mod/16S1RR-B.
All these specimens had been collected from inoculated cul-
ture bottles that had failed to exhibit signs of bacterial growth
during routine incubation. From one of the two positive speci-
mens (case XOR56), sequences obtained directly from the
PCR product and from two recombinant clones were identical
(at 535 positions) to the 16S rDNA sequence of a Staphylococ-
cus epidermidis type strain (ATCC 14990T, #D83363). From
the other PCR-positive blood culture specimen (case XCT29),
direct sequencing of the PCR products indicated the presence
of multiple, different DNA molecules. Five recombinant
clones were sequenced. Two clones were 99.8% (545/546 bp)
similar to 16S rDNA sequences from Enterococcus faecium
(strain DSM20477, #AJ276355) and E. durans (strain
DSM20633, #AJ276354). One clone was 99.8% similar to a
sequence from Bacillus stearothermophilus (strain IF012550,
#AB021196), one was 98.6% similar (509/516) to a sequence
from a Halomonas sp. (strain ML-028, #AF139994), and one
clone with a truncated sequence was 96.4% similar (323/335
bp) to several Bacillus species. The clinical relevance of the
rDNA findings in the etiology of these two cases remains
uncertain.
Table 2. Variability in the amplified Streptococcus pneumoniae 16S rDNA sequencesa
Pleural fluid Cerebrospinal fluid Bacterial isolates
XEB44b XMN22 XCA73c
Reference 
straind
Specimen 1-
PCR analysis 1
Specimen 
1-PCR
 analysis 2
Specimen 
1-PCR
 analysis
Specimen 
1-PCR analysis
Specimen 
2-PCR analysis
Corresponding 
E. coli  16S
 rDNA
position
Original 
PCR
 product
Clones 
from
 PCR 
products
Clones 
from 
PCR 
products
Clones 
from
 PCR 
products
Original
 PCR
 product
Clones 
from
 PCR 
products
Original
 PCR
 product
Clones 
from 
PCR 
products
A B C D E F G H I J K SF10
014
SF10
175
SF10
314
120 A/G G G A A A A A A AA A A AAAA A
260 A/G G A GGA GG G GG G G G G G G G
273 A A A A A A G A A AA A A AAAA A
279 A A A A G A A A A AA A A AAAA A
442 T T T T C TT T T T T T TT T T T T
a Nucleotides in bold differ with the reference strain sequence at the indicated rDNA position.
b One pleural fluid sample was analyzed with PCR on two occasions.
c Two cerebrospinal fluid specimens were taken 5 days apart from the same patient.
d Streptococcus pneumoniae NCTC 7465T (GenBank accession no. AJ001246).
E. coli = Escherichia coli; PCR = polymerase chain reaction.RESEARCH
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Discussion
In this study, we applied a molecular diagnostic method,
broad-range bacterial rDNA PCR, to 59 specimens from 46
UNEX cases. Positive findings were obtained for eight of the
cases. In six of these cases, the organism detected in the speci-
mens is a known cause of the type of syndrome the patient
had.
The diagnosis of infectious diseases with molecular data,
rather than from cultivation or serology, requires a careful
examination of criteria for causation (18) and may require new
molecular surveys of host microbial ecology. Streptococcus
pneumoniae and N. meningitidis are common causes of bacte-
rial meningitis in the United States (19), and S. pneumoniae is
a well-known cause of pneumonia and empyema. Despite
some unconfirmed reports of S. pneumoniae DNA in the
serum of healthy persons (20-22), our failure to find other bac-
terial sequences in the two pleural fluid specimens with broad-
range primers leads us to conclude that S. pneumoniae was the
cause of these two cases of respiratory tract disease. In CSF,
DNA from these organisms has been detected only in meningi-
tis cases. The response of project patients to appropriate anti-
biotics further supports these conclusions. Similarly, S.
maltophilia was the only bacterial species detected in a privi-
leged anatomic site (bone marrow) in case XOR63. The
known association of this organism with lower respiratory
tract disease and septicemia strongly suggests that it caused at
least some of this patient’s respiratory disease. However, addi-
tional specimens were not available for confirmation; in addi-
tion, S. maltophilia is ubiquitous in nature and, despite our
negative controls, may in theory contaminate laboratory
reagents. We speculate that it may have been acquired after the
patients admission to the hospital and contributed to the late
stages of the patient’s illness.
In the cases of multisystem failure (XOR56) and cardiac
disease (myocarditis, XCT29), the role played by the organ-
isms detected in the blood culture specimens in causing dis-
ease is much less clear. Although S. epidermidis was also
cultivated from the blood of case XOR56 by local physicians,
it is a well-recognized blood culture contaminant. Determining
its clinical relevance requires additional data. Bacillus sp. are
also occasional blood culture contaminants, and their DNA
may contaminate blood culture media (23). An Enterococcus
sp. is the most likely disease-causing agent among those
detected in case XCT29. In general, with reliance on molecu-
lar methods, conclusions about causation are most reliably
drawn after 1) repeated detection of the same organism in sep-
arate specimens from the same patient collected only at clini-
cally relevant time points; 2) direct detection of the organism
in situ in areas of pathology (24); 3) documentation of
response to appropriate therapy; and 4) assessment of specific
immune responses. Many of the same concerns and goals are
applicable to cultivation-based diagnosis. In practice, espe-
cially when case investigation occurs after resolution of illness
or death, as in this project, the preferred type and amount of
specimens are not always available.
Our findings from these “unexplained” cases raise several
important questions. Why weren’t these well-known bacterial
pathogens detected during the routine care of these patients?
Specimens are not always collected from the appropriate ana-
tomic site, at the appropriate time, in a sufficient amount, nor
processed in an optimal fashion. In addition, the sensitivity of
cultivation and serology is imperfect, even for organisms ame-
nable to these approaches. Most of the project patients had
received broad-range antibiotics before specimens were col-
lected for this study.
In applying broad-range rDNA PCR to clinical specimens,
one confronts the problem of 16S rDNA sequence microheter-
ogeneity. Small discrepancies between directly amplified
sequences and reference sequences in public databases pose
difficulties for the definition of taxon boundaries and compli-
cate clinical interpretation of laboratory data (25,26). In our
investigation, the finding of Streptococcus pneumoniae 16S
rDNA sequence microheterogeneity in the pleural fluid of a
patient with culture-negative empyema suggests that some
cases of pneumococcal disease, and perhaps other bacterial
disease, may be caused by multiple concurrent strains of the
same species.
Why have we failed to explain most of these project cases?
Are some unexplained cases caused by novel or previously
unrecognized pathogens? Our experiments addressed only the
possibility of a bacterial cause with bacterial domain-specific
broad-range PCR primers; current efforts include broad-range
primers for various families of viruses and for fungi and the
Archaea. Multiple broad-range primer pairs may be necessary
for each group (as we describe for the bacteria) to detect
unrecognized organisms with polymorphisms in conserved
primer recognition sites.
In addition to the specimen problems listed above, PCR
inhibitors may cause some false-negative results. The timing
of specimen acquisition may also be relevant, since the aver-
age delay between onset of illness and specimen collection
was 9 days for our PCR-positive cases versus 16 days for all
cases studied with broad-range PCR. Although bacterial DNA
persists longer than cultivatable organisms after therapy is ini-
tiated (27), the former still has a limited half-life. Finally, it
must be kept in mind that some of these cases may not have a
microbial cause.
Applying broad-range bacterial PCR to this set of difficult
clinical cases raised several important points about the future
use of this diagnostic approach. First, certain specimen types,
such as CSF (3/16 specimens positive), pleural fluid (2/3 posi-
tive), and bone marrow (1/2 positive), may provide higher
diagnostic yield in bacterial disease than other types, such as
serum and blood. Second, the microbial sequence “back-
ground” in clinical specimens from healthy persons (e.g.,
blood) must be better characterized before findings from ill
persons can be reliably interpreted. Third, sequence microhet-
erogeneity in anatomically isolated sites of microbial disease
may be more common than previously assumed. Our findings
from the XEB44 pleural fluid illustrate this point. There areEmerging Infectious Diseases  •  Vol. 8, No. 2, February 2002 193
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several possible explanations for the S. pneumoniae 16S
rDNA heterogeneity in this specimen (see above); however,
we believe that at least some of the heterogeneity is best
explained by the presence of two (or more) S. pneumoniae
strains. To our knowledge this is the first case of invasive dis-
ease associated with multiple S. pneumoniae strains, although
dual infections with other pathogens have been described
(28,29). In fact, carriage of multiple strains of Haemophilus
influenzae was recently shown to correlate with an increased
risk for otitis media in children (30), and mixed-strain infec-
tions with Mycobacterium tuberculosis have also been
reported (31). Multiple-strain infections with S. pneumoniae
may have been previously missed with culture-based methods
because of the common laboratory practice of subculturing a
single representative when there is only one apparent colony
morphotype.
The search for microbial causes of unexplained illnesses
and deaths must continue to integrate traditional and molecular
methods and will inevitably challenge assumptions about the
mechanisms of microbial disease causation. Refined tech-
niques, novel approaches, and study of other populations such
as immunocompromised or impaired hosts are likely to pro-
vide new insights into the spectrum of infectious diseases.
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